Kenvue Execs, J&J Face 2nd Investor Action Over FDA Probe

By Corey Rothauser ( January 19, 2024, 8:20 PM EST) -- Kenvue investors who bought into the multibillion-dollar pharmaceutical company's May 2023 initial public offering have named its executives and former parent company Johnson & Johnson in a proposed class action concerning their alleged failure to disclose the low efficacy of phenylephrine, an ingredient in cash cow nasal decongestants including Tylenol and Benadryl products....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!